Entrada Therapeutics (TRDA) Projected to Announce Earnings on Thursday

Entrada Therapeutics (NASDAQ:TRDA) is expected to issue its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect Entrada Therapeutics to post earnings of ($0.98) per share and revenue of $2.30 million for the quarter. Individuals may visit the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Friday, November 13, 2026 at 9:30 AM ET.

Entrada Therapeutics (NASDAQ:TRDA) last released its earnings results on Wednesday, August 5th. The company reported ($1.01) EPS for the quarter, missing the consensus estimate of ($0.97) by ($0.04). The business had revenue of $0.90 million for the quarter, compared to analyst estimates of $2.32 million. Entrada Therapeutics had a negative net margin of 3,537.73% and a negative return on equity of 57.61%. On average, analysts expect Entrada Therapeutics to post ($4.03) EPS for the current fiscal year and ($3.52) EPS for the next fiscal year.

Entrada Therapeutics Stock Performance

Shares of NASDAQ:TRDA opened at $4.72 on Wednesday. Entrada Therapeutics has a 1-year low of $4.11 and a 1-year high of $16.45. The company has a 50 day moving average price of $5.94 and a 200 day moving average price of $8.67.

Insider Transactions at Entrada Therapeutics

In other Entrada Therapeutics news, major shareholder Bioventures 2014 L.P. Mpm sold 14,569 shares of the company’s stock in a transaction dated Wednesday, August 26th. The shares were sold at an average price of $7.06, for a total transaction of $102,857.14. Following the completion of the sale, the insider directly owned 4,318,348 shares of the company’s stock, valued at approximately $30,487,536.88. This represents a 0.34% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, major shareholder Bioventures 2018 L.P. Mpm sold 28,837 shares of the firm’s stock in a transaction dated Wednesday, September 9th. The stock was sold at an average price of $7.13, for a total transaction of $205,607.81. Following the completion of the transaction, the insider owned 3,885,115 shares of the company’s stock, valued at approximately $27,700,869.95. The trade was a 0.74% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 714,013 shares of company stock valued at $5,111,237 over the last ninety days. Insiders own 9.49% of the company’s stock.

Analyst Ratings Changes

TRDA has been the topic of several research reports. Wall Street Zen cut Entrada Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday. Roth Capital reissued a “buy” rating and set a $11.00 price objective on shares of Entrada Therapeutics in a research note on Wednesday, August 12th. HC Wainwright reissued a “neutral” rating on shares of Entrada Therapeutics in a research note on Monday, October 19th. UBS Group restated a “neutral” rating on shares of Entrada Therapeutics in a report on Monday, October 19th. Finally, Weiss Ratings lowered Entrada Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, October 16th. Four equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Entrada Therapeutics has a consensus rating of “Hold” and a consensus target price of $17.75.

Entrada Therapeutics Company Profile

Entrada Therapeutics, Inc (NASDAQ:TRDA) is a biotechnology company focused on developing therapeutics designed to enter cells and address diseases caused by abnormal or missing intracellular proteins. The company’s approach is based on its Endosomal Escape Vehicle (EEV) platform, which is intended to deliver therapeutic payloads into target cells while helping them escape the endosome, a cellular compartment that can limit the effectiveness of some treatments.

Entrada is developing EEV-based medicines for serious diseases, particularly genetic and neuromuscular conditions.